Waters Cassis Discusses Q2 Rebound and Capital Equipment Market | GenomeWeb

Following a difficult first quarter in which it reported anemic organic revenue growth of 3 percent, Waters last week reported that its organic second-quarter revenues rose 8 percent year over year. The rebound brought relief to investors and others in the life sciences capital equipment market who have been closely monitoring pharma spending trends. This week, Gene Cassis, Waters' vice president of investor relations, spoke with BioCommerce Week about reasons for the firm's improved quarterly results and the current capital equipment market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.